Please try another search
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates. The company was founded in 2009 and is headquartered in Hangzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Fuqiang Jin | 61 | 2017 | Vice Chairman |
Deyi Zhao | 61 | 2015 | Director |
Dezhong Zhao | 56 | 2015 | Director |
Wenyan Hu | 54 | 2019 | Independent Director |
Biao Liu | 43 | 2018 | Chairman of the Board of Supervisors |
Yuming Pan | 62 | 2017 | Director |
Yan Jiang | 48 | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review